Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Respiratory Medicine

Journal Scan / Research · March 16, 2023

A Novel Radiogenomics Biomarker for Predicting Treatment Response to PD-1 or PD-L1 Inhibition Immunotherapy in Patients With NSCLC

Journal of Thoracic Oncology


Additional Info

Journal of Thoracic Oncology
A Novel Radiogenomics Biomarker for Predicting Treatment Response and Pneumotoxicity From Programmed Cell Death Protein or Ligand-1 Inhibition Immunotherapy in NSCLC
J Thorac Oncol 2023 Feb 09;[EPub Ahead of Print], M Chen, H Lu, SJ Copley, Y Han, A Logan, P Viola, A Cortellini, DJ Pinato, D Power, EO Aboagye

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading